Capital.com
UK retail investors are bullish on equities but worry about the cost-of-living crisis, falling stock prices and geopolitical risks in the year ahead.
LONDON, UK / ACCESSWIRE / January 26, 2024 / Seven in 10 retail (77%) traders and investors in the UK are taking a neutral-to-optimistic view on financial markets in 2024, according to a new nationally representative survey commissioned by online retail trading platform, Capital.com- with 35% of respondents expecting stocks to be the best performing asset class over the next six to 12 months. These findings affirm that market confidence among UK investors remains high, despite wider macro risks.
The findings are based on a nationally representative survey of 19,451 UK adults, of which 2,036 are traders or investors. In this survey, investors and traders are defined as adults who had invested or traded in mutual funds, bonds, forex, commodities, options, CFDs or spread bets in the past 12 months. The survey, commissioned by Capital.com and polled by Find Out Now, was carried out between 21 Nov to 4 Dec 2023.
Commenting on the upbeat investor sentiment revealed by the findings of the survey, Daniela Hathorn, Senior Market Analyst, Capital.com, said:
"Supported by positive economic data at the tail end of 2023, investors are perhaps approaching 2024 with an air of optimism. Yes, there are pockets of weakness in the economy, especially in the UK and the euro area, but global economic growth in 2023 has fared much better than expected. Of course that doesn't mean the same will happen in 2024, but with investors widely expecting interest rates to fall this year, many expect the recent resilience to be carried through as looser financing conditions make up for some of the loss in productivity and growth."
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.The survey further revealed a healthy interest in equity markets, with 35% of respondents expecting stocks to do well in 2024 followed by gold (32%) and oil & gas (31%). Positive market sentiment was further reflected in investors' capital allocation decisions with 30% of respondents saying they would buy or trade stocks in the next six to 12 months -with the majority focusing on growth and tech stocks (52%). Just 9% said they would move their capital into cash over the same period.
According to Daniela, investors' preference for stocks over other asset classes in 2024 is likely the result of improving market conditions.
"Stocks are typically favoured by investors because they are considered the ‘most tangible' of all non-physical investments, which simply means they are easier to measure and understand than other asset classes. Add to that expectations for rate cuts in 2024 and you have the ideal impetus for equity market enthusiasts. With the potential for lower interest rates in 2024, investors are perhaps expecting company valuations to improve making them attractive investments. Tech stocks are renowned for being the market sweethearts as they tend to hold their value even in difficult times, while offering investors greater returns. Similarly, growth stocks can benefit from improved market sentiment and higher valuations."
Cost-of-living crisis results in greater awareness of saving & investing activities
Despite the market optimism, respondents cited the ongoing cost-of-living crisis as the biggest risk to their investment and trading returns with 22% of those surveyed saying they would need to free up investment capital to cover higher expenses.
Consumers have less money to play with, putting pressure on many to amend their trading, savings and investment habits. When asked what they would do with an extra £10,000, the majority of respondents (57%) said they would either put it into a savings account or trade or invest it. Just 10% said they would spend it while 14% said they would overpay their mortgage or put it into a pension plan (6%).
To view this piece of content from www.accesswire.com, please give your consent at the top of this page."The recent period of high inflation has led to a general devaluation of capital unless it was invested in an asset that provided higher returns. It is not surprising that people are more conscious about how they manage their money now that they have seen the cost of living increase exponentially -it is no longer enough to simply save, consumers want to make up for the loss in their purchasing power. This has led to more awareness about investing, leading many to increase their capital allocations to return-generating activities rather than spending," said Daniela.
Other concerns for UK traders and investors in 2024 include falling stock prices (20%) , geopolitical risk (18%) and recession (16%). Tellingly, only 9% said that higher interest rates were of concern to them, suggesting investors expect the UK economy to improve in the year ahead.
"Markets are currently pricing in between five to six 25 bps rate cuts in 2024 from the BoE. Meanwhile, the central bank itself is expecting to make around three rate cuts this year. These misaligned expectations could drive momentum in UK assets over the coming months, especially as upcoming economic data reveals which set of expectations appear to be correct. Nonetheless, rate cuts are expected so investors may be looking to get higher yields on bonds while they can," she added.
END
Notes to Editors
About Capital.com
Capital.com is a high-growth fintech company empowering people to participate in financial markets through simple and innovative online trading platforms. Its intuitive award-winning platform, available on web and app, enables investors to trade thousands of world-renowned markets. To help investors trade with confidence, the platform is fitted with robust risk management controls and transparent pricing while its all-in-one ‘Investmate' app delivers financial lessons and educational content to support clients in their investment journey. Capital.com has a global network with offices located in Cyprus, UK and Australia.
Capital Com (UK) Limited is authorised and regulated by the Financial Conduct Authority (FCA) under registration number 793714. Capital Com SV Investments Limited is Authorised and regulated by the Cyprus Securities and Exchange Commission (CySEC), under licence number 319/17. Capital Com Australia Pty Ltd is authorised and regulated by the Australian Securities and Investments Commission (ASIC) under AFSL Number 513393.
To find out more, please visit: www.capital.com
Disclosures
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 75% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money. Professional clients can lose more than they deposit. All trading involves risk. Please refer to our Risk Disclosure Statement.
Crypto Derivatives are not available to Retail clients registered with Capital Com (UK) Ltd.
The value of shares and ETFs bought through a share dealing account can fall as well as rise, which could mean getting back less than you originally put in. Past performance is no guarantee of future results.
Capital Com (UK) Limited ("CCUK") is registered in England and Wales with company registration number 10506220. CCUK is authorised and regulated by the Financial Conduct Authority ("FCA"), under registration number 793714."
Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.
Any information which could be construed as "investment research" has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.
Shamillia Sivathambu
+44 79000 16469
shamillia.sivathambu@capital.com
SOURCE: Capital.com
View the original press release on accesswire.com
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Karbon-X Advances Community-Led Forest Protection in Colombia's Meta Region19.11.2025 15:00:00 CET | Press release
New phase of the Sur del Meta Project expands carbon and biodiversity monitoring while strengthening local governance and livelihoods. CALGARY, AB / ACCESS Newswire / November 19, 2025 / In the heart of Colombia's Meta department, where forests and farmlands converge, Karbon-X Corp. (OTCQX:KARX) ("Karbon-X" or the "Company") is deepening its commitment to people-powered climate solutions through the REDD+ Sur del Meta Project - a long-term conservation initiative that protects 40,637 hectares of natural forest while supporting sustainable livelihoods for nearly 1,000 local families. Developed through ALLCOT - A Karbon-X Company, the project development and advisory arm of Karbon-X, the initiative operates across the municipalities of Vistahermosa, Puerto Rico, Puerto Concordia, and Puerto Lleras, a region historically affected by deforestation and armed conflict. The project partners with local farmers, many of whom are victims of Colombia's armed conflict, helping them transition from
eComplete Partners with Sourceful to build AI-Native Creative Operations Across Portfolio18.11.2025 15:00:00 CET | Press release
MANCHESTER, UK / ACCESS Newswire / November 18, 2025 / eComplete, the private equity firm behind Current Body's £300 million London Stock Exchange listing, has announced a strategic partnership with Sourceful, the Manchester-based technology company whose Riverflow 1 model ranks as the world's leading AI image editing model. The partnership brings Sourceful's AI-native creative platform to eComplete's portfolio of direct-to-consumer brands, enabling them to generate brand-accurate, production-ready creative assets at scale across e-commerce, social, marketplace and retail. This makes eComplete the first major private equity investor to adopt AI-native creative infrastructure as a core operational advantage. Why this matters Every consumer brand today faces the same constraint: producing thousands of creative assets, product images, ads, videos, packaging, that feel authentically on-brand across every channel and market. This challenge has intensified dramatically over the past three ye
IXOPAY Appoints George Hansen as Chief Revenue Officer to Accelerate Global Growth in Tokenization, Orchestration, and Compliance18.11.2025 06:00:00 CET | Press release
Seasoned payments executive joins IXOPAY to lead global revenue strategy amid rapid growth and the rise of agentic commerce. LEHI, UTAH / ACCESS Newswire / November 18, 2025 / IXOPAY, a global leader in enterprise-grade payment orchestration, today announced the appointment of George Hansen as Chief Revenue Officer (CRO). A veteran of the payments and fintech industries, Hansen brings more than two decades of leadership experience driving growth, transformation, and customer-centric innovation at a global scale. In his new role, Hansen will drive IXOPAY's global revenue strategy, leading sales and partnerships and aligning with marketing and customer success to support enterprise merchants and partners worldwide. His appointment reinforces IXOPAY's commitment to giving merchants full control of their payment strategy through a vendor-neutral architecture designed for scale, flexibility, and intelligence. Hansen has held senior leadership positions at companies including American Expres
General Holdings Limited and NewOak Capital Form Strategic Joint Venture to Launch CMXG, an $800M Commodities Investment Platform18.11.2025 06:00:00 CET | Press release
DUBAI, AE / ACCESS Newswire / November 18, 2025 / General Holdings Limited (GH), a Dubai International Financial Centre-based multi-strategy private investment holding company, and NewOak Capital LLC, a New York collateralized private debt asset management and structured financing and capital markets firm, today announced the formation of Common Commodities CMXG (CMXG), a vertically integrated tech-enabled commodities investment platform designed to deliver risk-controlled, scalable institutional commodity-linked real yield and growth equity to qualified global investors. The partnership combines General Holdings' strategic capital and governance expertise with NewOak Capital's structured asset-based supply-chain financing capabilities and distribution platform. This sets the foundation for "a globally scalable, integrated and transparent institutional trade finance platform facilitating sustainable and inclusive cross-regional growth." Strategic Capital Deployment and Fund Launch CMXG
OBI-902 Has Been Granted by US FDA for Orphan Drug Designation for the Treatment of Cholangiocarcinoma17.11.2025 13:00:00 CET | Press release
OBI-902 is the first ADC utilizing OBI's proprietary GlycOBI® glycan-based ADC enabling technology for evaluation of safety and efficacy in patients with Cancer. TAIPEI, TW / ACCESS Newswire / November 17, 2025 / OBI Pharma, a clinical-stage oncology company (4174.TWO) received notification from the US FDA stating that the request for Orphan Drug Designation of OBI-902 TROP2 ADC for the treatment of Cholangiocarcinoma has been granted. OBI-902 is the first OBI-developed ADC that incorporates our proprietary site-specific glycan-conjugated ADC enabling technology. Cholangiocarcinoma is a rare and lethal malignancy with fewer than 50,000 patients in the United States and a 5-year survival rate ranging from 2% and 23% depending on disease stage, histological subtype, and localization 1 . At present, there are no FDA approved ADC therapies for cholangiocarcinoma. To encourage the industry to develop new treatment options for rare diseases, the US FDA grants Orphan Drug Designation to exper
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
